154 related articles for article (PubMed ID: 17373915)
1. Interaction between rifaximin and dietary fibre in patients with diverticular disease.
D'Incà R; Pomerri F; Vettorato MG; Dal Pont E; Di Leo V; Ferronato A; Medici V; Sturniolo GC
Aliment Pharmacol Ther; 2007 Apr; 25(7):771-9. PubMed ID: 17373915
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial.
Papi C; Ciaco A; Koch M; Capurso L
Aliment Pharmacol Ther; 1995 Feb; 9(1):33-9. PubMed ID: 7766741
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.
Latella G; Pimpo MT; Sottili S; Zippi M; Viscido A; Chiaramonte M; Frieri G
Int J Colorectal Dis; 2003 Jan; 18(1):55-62. PubMed ID: 12458383
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group.
Papi C; Ciaco A; Koch M; Capurso L
Ital J Gastroenterol; 1992 Oct; 24(8):452-6. PubMed ID: 1330083
[TBL] [Abstract][Full Text] [Related]
5. Cyclic antibiotic therapy for diverticular disease: a critical reappraisal.
Zullo A; Hassan C; Maconi G; Manes G; Tammaro G; De Francesco V; Annibale B; Ficano L; Buri L; Gatto G; Lorenzetti R; Campo SM; Ierardi E; Pace F; Morini S
J Gastrointestin Liver Dis; 2010 Sep; 19(3):295-302. PubMed ID: 20922195
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effect of rifaximin in colon diverticular disease by means of lactulose hydrogen breath test.
Ventrucci M; Ferrieri A; Bergami R; Roda E
Curr Med Res Opin; 1994; 13(4):202-6. PubMed ID: 7882699
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease.
Bianchi M; Festa V; Moretti A; Ciaco A; Mangone M; Tornatore V; Dezi A; Luchetti R; De Pascalis B; Papi C; Koch M
Aliment Pharmacol Ther; 2011 Apr; 33(8):902-10. PubMed ID: 21366632
[TBL] [Abstract][Full Text] [Related]
8. Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test.
Biancone L; Vernia P; Agostini D; Ferrieri A; Pallone F
Curr Med Res Opin; 2000; 16(1):14-20. PubMed ID: 16422030
[TBL] [Abstract][Full Text] [Related]
9. [Role of rifaximin in the treatment of colonic diverticular disease].
Moretti A; Spagnolo A; Mangone M; Chiesara F; Aratari A; Papi C; Koch M
Clin Ter; 2012; 163(1):33-8. PubMed ID: 22362232
[TBL] [Abstract][Full Text] [Related]
10. Rifaximin in the management of colonic diverticular disease.
Latella G; Scarpignato C
Expert Rev Gastroenterol Hepatol; 2009 Dec; 3(6):585-98. PubMed ID: 19929580
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease.
Colecchia A; Vestito A; Pasqui F; Mazzella G; Roda E; Pistoia F; Brandimarte G; Festi D
World J Gastroenterol; 2007 Jan; 13(2):264-9. PubMed ID: 17226906
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth.
Majewski M; Reddymasu SC; Sostarich S; Foran P; McCallum RW
Am J Med Sci; 2007 May; 333(5):266-70. PubMed ID: 17505166
[TBL] [Abstract][Full Text] [Related]
13. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence.
Sharara AI; Aoun E; Abdul-Baki H; Mounzer R; Sidani S; Elhajj I
Am J Gastroenterol; 2006 Feb; 101(2):326-33. PubMed ID: 16454838
[TBL] [Abstract][Full Text] [Related]
14. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test.
Low K; Hwang L; Hua J; Zhu A; Morales W; Pimentel M
J Clin Gastroenterol; 2010 Sep; 44(8):547-50. PubMed ID: 19996983
[TBL] [Abstract][Full Text] [Related]
15. Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics.
Cuoco L; Montalto M; Jorizzo RA; Santarelli L; Arancio F; Cammarota G; Gasbarrini G
Hepatogastroenterology; 2002; 49(48):1582-6. PubMed ID: 12397741
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.
Taylor DN; Bourgeois AL; Ericsson CD; Steffen R; Jiang ZD; Halpern J; Haake R; Dupont HL
Am J Trop Med Hyg; 2006 Jun; 74(6):1060-6. PubMed ID: 16760520
[TBL] [Abstract][Full Text] [Related]
17. Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease.
Chang MS; Minaya MT; Cheng J; Connor BA; Lewis SK; Green PH
Dig Dis Sci; 2011 Oct; 56(10):2939-46. PubMed ID: 21647654
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.
Adachi JA; DuPont HL
Clin Infect Dis; 2006 Feb; 42(4):541-7. PubMed ID: 16421799
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.
Furnari M; Parodi A; Gemignani L; Giannini EG; Marenco S; Savarino E; Assandri L; Fazio V; Bonfanti D; Inferrera S; Savarino V
Aliment Pharmacol Ther; 2010 Oct; 32(8):1000-6. PubMed ID: 20937045
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin in patients with lactose intolerance.
Cappello G; Marzio L
Dig Liver Dis; 2005 May; 37(5):316-9. PubMed ID: 15843080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
